Review Article
Physiological Role of Plasmacytoid Dendritic Cells and Their Potential Use in Cancer Immunity
| Tumor | System | DC source | Protocol | References |
| EG7 T-cell lymphoma | Murine | Expanded in vivo (FLt3L),
and sorted
from BM | CpG-activated OVAp-pulsed pDCs/mDCs | Lou et al. [109] (2007) |
| K17-35-OVA melanoma | Murine | Isolated
TIDCs from K17-35
melanoma | OVA-pulsed
TIDCs | Preynat-Seauve et al. [110]
(2006) |
| C26
colon Carcinoma | Murine | Isolated
TIDCs from C26
tumor | TIDCs
activated with CpG +
anti-IL-10R (i.p.) | Vicari et al. [111] (2002) |
| M3 Melanoma | Murine | ā | Topical
application Imiquimod | Palamara et al. [46] (2004) |
| Melanoma cell
lines | Human | Sorted
from PBMC | pDCs
activated with CD40L-transfected
J558 | Salio et al. [42] (2003) |
| Melanoma stage
IIIb/c, IV | Human | ā | CpG-7909
(s.c.) (ProMune) | Pashenkov et al. [112] (2006) |
|
|
DCs,
dendritic cells; pDCs, plasmacytoid DCs; BM, bone-marrow; OVAp, OVA peptide; TIDCs,
tumor-infiltrating DCs (myeloid and plasmacytoid); PBMC, peripheral blood
mononuclear cells.
|